SCHEMBL4394378

SCHEMBL4394378

CC(C)(CO)Nc1nc(-c2ccc(Br)cc2F)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
AGER Q15109 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
VCP P55072 1/20 0.39
MAOA P21397 6/20 0.39
MAOB P27338 6/20 0.39
LATS1 O95835 1/20 0.39
LATS2 Q9NRM7 1/20 0.39
CYP1B1 Q16678 1/20 0.39
TYR P14679 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
CSNK2A1 P68400 1/20 0.37
MPL P40238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077729 0.80 MAPT (0.59) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4078682 0.78 MEN1 (0.52) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3977673 0.74 ABL1 (0.62) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4077757 0.73 MPL (0.46) MAPTNPC1RAB9AAGERMEN1
SCHEMBL3527848 0.71 SIRT5 (0.48) RAB9AMEN1KMT2AVCP
SCHEMBL4083643 0.68 PIK3CG (0.39) LMNAVCP
SCHEMBL3175801 0.67 VCP (0.58) MAPTMEN1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL4078444 0.67 PIK3CG (0.38) LMNAVCP
SCHEMBL22753407 0.66 MAPT (0.65) MAPTNPC1RAB9AAGERMEN1
SCHEMBL3166410 0.66 CYP1A1 (0.51) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR MAPT 1550/4885NPC1 4830/4885RAB9A 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.